TY  - JOUR
A1  - Mansour, Ahmad M.
A1  - Arevalo, J. Fernando
A1  - Al Kahtani, Eman
A1  - Zegarra, Hernando
A1  - Abboud, Emad
A1  - Anand, Rajiv
A1  - Ahmadieh, Hamid
A1  - Sisk, Robert A.
A1  - Mirza, Salman
A1  - Tuncer, Samuray
A1  - Navea Tejerina, Amparo
A1  - Mataix, Jorge
A1  - Ascaso, Francisco J.
A1  - Pulido, Jose S.
A1  - Guthoff, Rainer
A1  - Goebel, Winfried
A1  - Roh, Young Jung
A1  - Banker, Alay S.
A1  - Gentile, Ronald C.
A1  - Alonso Martinez, Isabel
A1  - Morris, Rodney
A1  - Panday, Neeraj
A1  - Min, Park Jung
A1  - Merce, Emilie
A1  - Lai, Timothy Y. Y.
A1  - Massoud, Vicky
A1  - Ghazi, Nicola G.
T1  - Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
JF  - Journal of Ophtamology
N2  - We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0.001), 105.3 microns at 1 year (n = 10; P = 0.03), and 157.6 microns at 2 years (n = 7; P = 0.08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P < 0.001), 2.8 lines (n = 20; P = 0.01) at 1 year, and 3.1 lines (n = 13; P = 0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.
KW  - membrane
KW  - photodynamic therapy
KW  - secondary
KW  - bevacizumab
KW  - ranibizumab
KW  - patient
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117923
IS  - 210458
ER  - 
TY  - JOUR
A1  - Schroeder, Katharina
A1  - Meyer-ter-Vehn, Tobias
A1  - Fassnacht-Riederle, Heidi
A1  - Guthoff, Rainer
T1  - Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report
JF  - Journal of Medical Case Reports
N2  - Background:
Multifocal choroiditis with panuveitis is a rare disease. The educational merit of this case presentation results from the good documentation and the impressive ocular fundus pictures.

Case presentation:
We illustrate the 3-year course of disease in a 22-year-old myopic white woman with multifocal choroiditis with panuveitis and secondary choroidal neovascularization. The activity of the disease was evaluated clinically by optical coherence tomography and fluorescein angiography. Choroidal neovascularization was treated by intravitreal bevacizumab (2.5 mg/0.1 ml). Our patient lacked systemic therapy for the first 11 months because of noncompliance.

Conclusions:
The case is remarkable as the delayed onset of peripheral lesions and the additional existence of high myopia made diagnosis difficult. In addition, it demonstrates that full outbreak of disease with multiple central and peripheral fundus lesions and secondary choroidal neovascularization can develop without systemic treatment.
KW  - multifocal choroiditis
KW  - chorioretinal lesions
KW  - secondary CNV
KW  - bevacizumab
KW  - systemic immunosuppression
KW  - case report
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-171317
VL  - 10
IS  - 298
ER  -